<DOC>
	<DOCNO>NCT00502216</DOCNO>
	<brief_summary>The purpose study determine whether combination naltrexone ( Depade ) varenicline ( Chantix ) minimize post-smoking cessation weight gain well combination tolerate .</brief_summary>
	<brief_title>Naltrexone Varenicline : Weight Gain Tolerability Cigarette Smokers</brief_title>
	<detailed_description>Varenicline , medication recently approve FDA , result smoke cessation rate high 50 % , significantly good bupropion placebo . However , varenicline reduce post-cessation weight gain , weight concern may keep smoker take advantage effective therapy . A potential solution would combine varenicline agent reduces weight gain . In regard , several study show naltrexone reduces weight gain ( O'Malley et al. , 2006 ; Toll et al. , 2007 ) . This effect appear dose dependent , favor low dos ( i.e. , 25 mg daily ) . Thus , propose study seek conduct pilot clinical trial low dose naltrexone ( 25 mg daily ) compare placebo minimize weight gain combination varenicline smoke cessation . Forty individual smoke least 10 cigarette per day receive open-label varenicline 12 week accord recommended titration schedule 1 mg varenicline twice daily . Subjects randomize receive either placebo 25 mg naltrexone daily , treatment start quit date ( 1 week varenicline minimize nausea , side effect varenicline naltrexone ) continue 11 week . Subjects take 12.5 mg naltrexone daily first week 25 mg naltrexone daily next 10 week treatment . In effort uncover mechanisms naltrexone 's weight suppressant effect , experiment conduct use food odor food consumption examine naltrexone 's effect palatability , incentive value , alliesthesia . This experiment conduct pretreatment 2 week naltrexone . The primary aim pilot study examine weight gain participant complete clinical trial treatment . Weight gain continuously abstinent last 4 week treatment rate adverse event secondary outcome . The effect naltrexone odor/food palatability , incentive value , alliesthesia exploratory outcome . Effect size estimate weight gain generate NIH grant application .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Between age 18 75 2 . Smoking 10 cigarette per day 3 . Fewer 3 month smoke abstinence past year 4 . Motivated stop smoking 1 . Current use opiate , and/or urine toxicology screen positive opiates 2 . Chronic pain condition necessitate opioid treatment ( naltrexone , opioid antagonist make medication ineffective ) 3 . Evidence significant hepatocellular injury evidence AST ALT &gt; 3 x normal elevate bilirubin 4 . History cirrhosis 5 . Any serious unstable disease within 6 month 6 . Seizure risk 7 . Diabetes mellitus require insulin oral hypoglycemic medication 8 . Hepatic renal impairment 9 . Use monoamine oxidase inhibitor prior 14 day 10 . Clinically significant cardiovascular disease within 6 month 11 . Uncontrolled hypertension 12 . Baseline systolic blood pressure high 150 mm Hg diastolic blood pressure high 95 mm Hg 13 . Severe chronic obstructive pulmonary disease 14 . History cancer ( except treat basal cell squamous cell carcinoma skin ) 15 . History clinically significant allergic reaction 16 . Major depressive disorder within past year require treatment 17 . History current panic disorder , psychosis , bipolar disorder , eat disorder 18 . Alcohol drug abuse/dependency within past year 19 . Use another investigational drug within 30 day 20 . Intention donate blood blood product treatment phase study 21 . Use tobacco product cigarettes use marijuana 22 . Use nicotine replacement therapy , clonidine , varenicline , bupropion , nortriptyline within month prior enrollment intention use medication might interfere study medication 23 . Body Mass Index ( calculate weight kilogram divide square height meter ) less 15 great 38 weight less 45 kg . 24 . Females childbearing potential pregnant , nursing , practice effective contraception ( oral injectable , implantable contraceptive , intrauterine device , barrier method spermacide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Tobacco</keyword>
	<keyword>Smoking</keyword>
	<keyword>Weight</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Varenicline</keyword>
</DOC>